apratastat and Psoriasis

apratastat has been researched along with Psoriasis* in 1 studies

Other Studies

1 other study(ies) available for apratastat and Psoriasis

Article	Year
Identification of novel TACE inhibitors compatible with topical application. Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8 Targeting the Tumor Necrosis Factor α signalling with antibodies has led to a revolution in the treatment of psoriasis. Locally inhibiting Tumor Necrosis Factor α Converting Enzyme (TACE or ADAM17) could potentially mimic those effects and help treat mild to moderate psoriasis, without the reported side effect of systemic TACE inhibitors. Efforts to identify new TACE inhibitors are presented here. Enzymatic SAR as well as ADME and physico-chemistry data are presented. This study culminated in the identification of potent enzymatic inhibitors. Suboptimal cellular activity of this series is discussed in the context of previously published results. Topics: ADAM17 Protein; Administration, Topical; Enzyme Inhibitors; Humans; Hydroxamic Acids; Psoriasis	2017

Article

Year

Identification of novel TACE inhibitors compatible with topical application.

Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8

Targeting the Tumor Necrosis Factor α signalling with antibodies has led to a revolution in the treatment of psoriasis. Locally inhibiting Tumor Necrosis Factor α Converting Enzyme (TACE or ADAM17) could potentially mimic those effects and help treat mild to moderate psoriasis, without the reported side effect of systemic TACE inhibitors. Efforts to identify new TACE inhibitors are presented here. Enzymatic SAR as well as ADME and physico-chemistry data are presented. This study culminated in the identification of potent enzymatic inhibitors. Suboptimal cellular activity of this series is discussed in the context of previously published results.

Topics: ADAM17 Protein; Administration, Topical; Enzyme Inhibitors; Humans; Hydroxamic Acids; Psoriasis

2017